Sestre Milosrdnice University hospital and Institute of Clinical Medical Research
Abstract
Parkinson\u27s disease is one of the most common neurodegenerative diseases caused by degeneration of dopaminergic neurons in substantia nigra. The neuropathologic hallmark of Parkinson\u27s disease is the presence of Lewy bodies composed mostly of alpha-synuclein and ubiquitin. It is believed that the occurrence of Parkinson\u27s disease is due to a combination of genetic and environmental factors, but the exact mechanism of Parkinson\u27s disease development is not fully elucidated. The most characteristic motor symptoms for Parkinson\u27s disease include bradykinesia, rigidity, resting tremor and postural instability, while many patients also have non-motor signs and symptoms. The key therapeutic agent in the treatment of Parkinson\u27s disease is L-dopa, and the others are dopaminergic agents, monoamine oxidase-B (MAO-B) inhibitors, catechol-O-methyl transferase (COMT) inhibitors, amantadine and anticholinergic agents.Parkinsonova bolest je jedna od najčešćih neurodegenerativnih bolesti koju uzrokuje degeneracija dopaminergičnih neurona u supstanciji nigri. Neuropatološko obilježje Parkinsonove bolesti je nalaz Lewyjevih tjelešaca koja su najvećim dijelom građena od alfa sinukleina i ubikvitina. Pojavu Parkinsonove bolesti uzrokuje međudjelovanje genetskih čimbenika i čimbenika iz okoliša, ali točan mehanizam nastanka bolesti nije u potpunosti poznat. Najznačajniji motorni simptomi bolesti su bradikinezija, rigiditet, tremor u mirovanju i posturalna nestabilnost. Najznačajniji lijek u liječenju Parkinsonove bolesti je L-dopa, a primjenjuju se i dopaminergični agonisti, inhibitori monoaminooksidaze B (MAO-B), inhibitori katehol-O-metil transferaze (COMT), amantadin i anukolinergični lijekovi
